Astria Therapeutics Says STAR-0310 Showed Half-Life of 68 Days in Phase 1a Trial; Shares Up Pre-Bell

MT Newswires Live

2025/09/17

Astria Therapeutics (ATXS) said Wednesday its STAR-0310 showed a half-life of up to 68 days, consistent with administration every six months, along with cytokine suppression lasting for at least 20 weeks during its phase 1a trial.

Shares of the company were up more than 4% in recent Wednesday premarket activity.

The company further said that STAR-0310 was observed to be well-tolerated at all dose levels, with no serious treatment-emergent adverse events or discontinuations.

STAR-0310 is a YTE half-life extended monoclonal antibody antagonist of OX40, a type of protein.

Price: 7.60, Change: +0.33, Percent Change: +4.54

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2568496342"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2568496342\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2568496342?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-17 20:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2568496342","market":"sh","top_or_hot":-1,"title":"Astria Therapeutics Says STAR-0310 Showed Half-Life of 68 Days in Phase 1a Trial; Shares Up Pre-Bell","media":"MT Newswires Live","content":"<html><body><p> Astria <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ATXS) said Wednesday its STAR-0310 showed a half-life of up to 68 days, consistent with administration every six months, along with cytokine suppression lasting for at least 20 weeks during its phase 1a trial.</p><p>Shares of the company were up more than 4% in recent Wednesday premarket activity.</p><p>The company further said that STAR-0310 was observed to be well-tolerated at all dose levels, with no serious treatment-emergent adverse events or discontinuations.</p><p>STAR-0310 is a YTE half-life extended monoclonal antibody antagonist of OX40, a type of protein.</p><p>Price: 7.60, Change: +0.33, Percent Change: +4.54</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Astria Therapeutics Says STAR-0310 Showed Half-Life of 68 Days in Phase 1a Trial; Shares Up Pre-Bell</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstria Therapeutics Says STAR-0310 Showed Half-Life of 68 Days in Phase 1a Trial; Shares Up Pre-Bell\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-17 20:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Astria <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ATXS) said Wednesday its STAR-0310 showed a half-life of up to 68 days, consistent with administration every six months, along with cytokine suppression lasting for at least 20 weeks during its phase 1a trial.</p><p>Shares of the company were up more than 4% in recent Wednesday premarket activity.</p><p>The company further said that STAR-0310 was observed to be well-tolerated at all dose levels, with no serious treatment-emergent adverse events or discontinuations.</p><p>STAR-0310 is a YTE half-life extended monoclonal antibody antagonist of OX40, a type of protein.</p><p>Price: 7.60, Change: +0.33, Percent Change: +4.54</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2568496342","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2568496342","pubTimestamp":1758112157,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Astria Therapeutics (ATXS) said Wednesday its STAR-0310 showed a half-life of up to 68 days, consistent with administration every six months, along with cytokine suppression lasting for at least 20 we","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4007":"制药","ATXS":"Astria Therapeutics Inc","BK4539":"次新股","LENZ":"Therapeutics"},"translate_title":"Astria Therapeutics表示，STAR-0310在1a期试验中显示半衰期为68天；分享盘前","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"ATXS":1},"content_text":"Astria Therapeutics (ATXS) said Wednesday its STAR-0310 showed a half-life of up to 68 days, consistent with administration every six months, along with cytokine suppression lasting for at least 20 weeks during its phase 1a trial.Shares of the company were up more than 4% in recent Wednesday premarket activity.The company further said that STAR-0310 was observed to be well-tolerated at all dose levels, with no serious treatment-emergent adverse events or discontinuations.STAR-0310 is a YTE half-life extended monoclonal antibody antagonist of OX40, a type of protein.Price: 7.60, Change: +0.33, Percent Change: +4.54","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}